Table 1.
Variable | Test-cohort (mRNA) n (%) | Validation-cohort (TMA) n (%) |
---|---|---|
Sex | ||
Male | 86 (57·7) | 87 (61·7) |
Female | 63 (42·3) (missing: 47) |
54 (38·3) |
Age at diagnosis | ||
<15 years | 112 (59·3) | 70 (49·7) |
≥15 years | 77 (40·7) | 71 (50·3) |
Metastasis at diagnosis | ||
Absent | 53 (69·7) | 87 (61·7) |
Present | 23 (30·3) (missing: 113) |
54 (38·3) |
Sitea | ||
Axial | NA | 86 (61·9) |
Non-axial | NA | 53 (38·1) (missing: 2) |
Tumour volume | ||
<200 ml | NA | 76 (55·9) |
<200 ml | NA | 60 (44·1) (missing: 5) |
Histological responseb | ||
Good | NA | 67 (79·8) |
Poor | NA | 17 (20·2) (missing: 57) |
Status | ||
Alive | 113 (59·8) | 84 (59·6) |
Dead | 76 (40·2) | 57 (40·4) |
SOX2 expression | ||
High | 38 (20·1) | 22 (15·6) |
Low | 151 (79·9) | 119 (84·4) |
All extremity localization are non-axial.
NA = not available.